1Kirst HA, Sides GD. Minirevews:New directions for macrolide antibiotics:structure modification and in vitro activity. Antimicrob Agents Cbemother,1989,33:1413.
2Kirst HA, Sides GD. New directions for macrolide antibiotics: pbarmacokinetics and clinical efficacy. Antimicrob Agents Chemother, 1989,33:1419.
3Chu S Y, Setnnello L T, Bunnell S T, et al. Pharmacokinetics of clarithromycin, a new macrolide, after single ascending oral dosc. Antimicrob Agents Chemother.1992,36:2447.
4Hardy D J. Swanson R N, Rode RA. et al. Enhancement of the in vitro and in vivo activities of clarithromycin against Haemophilus influenzae by 14-bydroxy-clarithromycin, ts major metabolite in humans. Antimicrob Agents Chemother,1990.34: 1407.
5Kohno Y, Yoshida H.Suwa T, et al.Comparative pharmacokinetics of clarrthromycin(TE-031). a new macrolide autibiotic, and erythromycin in rats. Antimicrob Agents Chemothe, 1989.33: 751.
6Parish L C, Clarithromycin study group. Clarithromycin in the treatment of skin and skin structure infections: two multicenter clinical studies. Int J Dermatol,1993,32(7); 528.
7Bradbury F. Comparison of azithromycin versus clarithromycin in the treatment of patients with lower respiratory tract infection. J Antimicrob Chemother, 1993,31(Sappl E): 153.
8Muller O. Comparison of azithromycin versus clarithromycin in the treatment of patients with upper respiratory tract infections. J Antimicrob Chemother. 1993.31(Suppl E): 137.
9Benson C A, Segreti J, Beaudette F E, et al. In vitro activity of A-56268 (TE031), a new macrolide, compared with that of erythromycin and clindamycin against selecled gram-positive and gram-negative organisms. Antimicrob Agents Chemotber, 1987,31:328.
10Barry A 1, Thomsberry C, Jones R N. In vitro activity of a new macrolide, A-56268,compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrob Agents Chemother, 1987.31: 343.
